Ge Long Hui·2025-09-30 10:33Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received approval from the National Medical Products Administration to conduct clinical trials for HLX43 and HLX07 in treating advanced/metastatic solid tumors [1] Group 1: Clinical Trial Approval - The company has been granted permission to initiate clinical trials for the combination treatment of HLX43 and HLX07 [1] - The clinical trials will be conducted in mainland China, excluding Hong Kong, Macau, and Taiwan [1] Group 2: Drug Details - HLX43 is a targeted PD-L1 antibody-drug conjugate developed by linking a novel DNA topoisomerase I inhibitor with a self-developed PD-L1 targeting antibody [1] - HLX07 is an innovative biological drug developed by the company targeting the EGFR pathway, intended for the treatment of advanced solid tumors [1]